This is a news story, published by CNBC, that relates primarily to Novo Nordisk news.
For more drug discoveries news, you can click here:
more drug discoveries newsFor more news from CNBC, you can click here:
more news from CNBCOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
Novo Nordisk. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest drug Ozempic news, earnings news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
Danish pharmaceutical giantCNBC
•
78% Informative
Danish pharmaceutical giant Novo Nordisk reported third quarter earnings broadly in line with expectations.
Net profit in the third quarter hit 27.3 billion Danish kroner ( $3.92 billion ) The company also narrowed its sales growth guidance for the full year 2024 to 23% to 27% at constant exchange rates.
VR Score
88
Informative language
93
Neutral language
56
Article tone
formal
Language
English
Language complexity
52
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links